The Future of Triplets and Doublets

I think it's an exciting time, but sometimes these questions are tough to answer just because the treatments themselves currently are just so good right now. I was fortunate enough to present on behalf of the authors the update from Captivate showing these patients who are in deep MRD negative remissions. How are they doing on placebo versus continuation and again, establishing the relevance of fixed duration. Talamunir presented the FLAIR study. This is a limited analysis, but there were some helpful things there. And then Catherine Ryan from Matt David's group and Dana Farber presented his updated multi-center phase two study from AVO. So we'll be narrowing in who it is that may fail